To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma (NCT06344052)
A Phase 2 Study to Assess the Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma
🩺 Plain-English Summary (8th-Grade Level)
The goal of this clinical trial is to evaluate the efficacy of using SP-002 in participants with locally advanced Basal cell carcinoma. The main question it aims to answer is what the objective response rate for a basal cell carcinoma tumor is following 1 or 3 cycles of SP-002 treatment given as an add-on to hedgehog pathway inhibitor therapy. Researchers will compare the objective response rate for treated Basal cell carcinoma tumors between 3 treatment Arms. * Arm 1 participants will receive daily hedgehog pathway inhibitor, and 3 cycles of SP-002 treatment. * Arm 2 participants will receive daily hedgehog pathway inhibitor, and 1 cycle of SP-002 treatment. * Arm 3 participants will receive daily hedgehog pathway inhibitor only.
Who can join: Review the eligibility criteria below.
Location: Research Site — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (10 Sites)
- Research Site — Phoenix, Arizona
- Research Site — Boca Raton, Florida
- Research Site — Coral Springs, Florida
- Research Site — Cutler Bay, Florida
- Research Site — Rockville, Maryland
- Research Site — Lee's Summit, Missouri
- Research Site — Rochester, New York
- Research Site — Cedar Park, Texas
- Research Site — Humble, Texas
- Research Site — Longview, Texas
📞 Contact the Study Coordinator
Phone: (512) 694-4241
Email: clinicaltrials@stamfordpharmaceuticals.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Basal Cell Carcinoma
- Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II) — West Palm Beach, Florida
- A Study of Observation and Follow-up in People With Basal Cell Carcinoma — New York, New York
- Optical Coherence Tomography Guided Laser Treatment of Basal Cell Carcinoma — Irvine, California
- A Study on Radiation Therapy Guided by the Reflectance Confocal Microscopy (RCM)/Optical Coherence Tomography (OCT) Device in People With Basal Cell Carcinoma — Basking Ridge, New Jersey
- Alteration of the Immune Microenvironment in Basal Cell Carcinoma Following Photodynamic Therapy — Cleveland, Ohio
- Basal Cell Carcinoma Chemoprevention Trial — Providence, Rhode Island
Explore by condition: All Basal Cell Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.